Results 111 to 120 of about 6,174 (184)

Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma. [PDF]

Clin Cancer Res
Dummer R, Deng S, Xie T, Pathan N, Saffari H, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandala M, Schadendorf D, Yamazaki N, Ascierto PA, Davis CB, Shah K, Hamilton P, di Pietro A, Flaherty K.   +22 more
europepmc   +1 more source

A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer. [PDF]

Future Oncol
Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ.   +20 more
europepmc   +1 more source

A study to learn how well the combination of encorafenib and binimetinib works and how safe it is in adults with thyroid cancer: a plain language summary. [PDF]

Future Oncol
Tahara M, Kiyota N, Imai H, Takahashi S, Nishiyama A, Tamura S, Shimizu Y, Kadowaki S, Ito KI, Hirashima Y, Ueno S, Sugitani I.   +11 more
europepmc   +1 more source

Updated result from the phase 2 PHAROS study: has the sustained efficacy and tolerability of encorafenib plus binimetinib been demonstrated in patients with <i>BRAF</i> V600E-mutant metastatic non-small-cell lung cancer? [PDF]

J Thorac Dis
Yonesaka K.
europepmc   +1 more source

Antitumor Activity of Metformin in Combination with Binimetinib Against Melanoma Cells. [PDF]

Int J Mol Sci
Wolan R, Wawszczyk J, Orchel A, Kapral M.   +3 more
europepmc   +1 more source

Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF‑mutated metastatic colorectal cancer: the BEETS (JACCRO CC‑18) study. [PDF]

Oncologist
Kotani D, Inoue E, Denda T, Inagaki C, Kashiwada T, Mihara Y, Sugaya A, Suwa Y, Ohta T, Kuramochi H, Oshima K, Yuki S, Shiozawa M, Tsuji A, Muro K, Ichikawa W, Fujii M, Sunakawa Y.   +17 more
europepmc   +1 more source

Implementation of a lifestyle‐based clinical pathway in daily clinical practice in men undergoing androgen deprivation therapy for prostate cancer [PDF]

, 2019
Bruggeman, Anniek, Bultijnck, Renée, De Muynck, Martine, Decaestecker, Karel, Deforche, Benedicte, Fonteyne, Valerie, Lumen, Nicolaas, Mortier, Stefanie, Ost, Piet, Raes, Anneleen, Rammant, Elke, Van Ruymbeke, Barbara   +11 more
core   +1 more source

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series. [PDF]

Front Endocrinol (Lausanne)
Yamin T, Cohen O, Robenshtok E, Izkhakov E, Miodovnik M, Gutfeld O, Leshem Y, Meirovitz R, Warshavsky A, Muhanna N, Finkel I.   +10 more
europepmc   +1 more source

Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. [PDF]

Oncologist
Haldar SD, Saj F, Hong SJ, Surana R, Xiao L, Lee JJ, Smaglo B, Zhao D, Zhu H, Huey R, Willis J, Morelli MP, Overman M, McAllister F, Wolff R, Maitra A, Fogelman D, Der C, Pant S.   +18 more
europepmc   +1 more source

Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies. [PDF]

Nat Commun
Manabe T, Bergo HC, Li Q, Wang TS, Severson P, Miller N, Lee C, Yay Donderici E, Zhang N, Wu W, Chou YT, Kerr DL, Allegakoen P, Grandinetti KB, Soroceanu L, Pelham RJ, Martin ES, Murphy EA, Khanna V, Neal JW, Chen CT, Kato S, Williams R, Bivona TG.   +23 more
europepmc   +1 more source